Research programme: inflammatory bowel disease therapy - BioLineRx
Alternative Names: BL-1030Latest Information Update: 09 May 2007
At a glance
- Originator Rimonyx Pharmaceuticals
- Class Small molecules
- Mechanism of Action L-selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 19 Jan 2005 Preclinical trials in Inflammatory bowel disease in Israel (unspecified route)